Cancer Pain
📧 Sign up to get email alerts when something new happens for Cancer Pain.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-06-11FDA Approved: FENTANYL TRANSDERMAL — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for Fentanyl Transdermal filed by SpecGx LLC.
-
CLINICAL_TRIALS trial_result · 2015-06-01Clinical Trial Update: Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain [Phase 3]
A Phase 3 trial evaluated efficacy and safety of a treatment for opioid-induced constipation in patients with cancer-related pain. The study…
-
FDA approval · 2015-01-20FDA Approved: FENTANYL CITRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for fentanyl citrate submitted by Hikma Pharmaceuticals USA Inc., resulting in updated regulatory ap…
-
CLINICAL_TRIALS trial_result · 2015-01-01Clinical Trial Update: A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain [Phase 2]
Phase 2 study evaluating the safety, tolerability, and efficacy of ARX-F02 (Sufentanil NanoTab) versus placebo for cancer breakthrough pain;…
-
FDA approval · 2014-08-19FDA Approved: FENTANYL TRANSDERMAL — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for fentanyl transdermal patch from SpecGx LLC, resulting in approval of an additional generic produ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2014-06-23Clinical Trial Update: Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery [NA]
A clinical trial is evaluating a personalized care plan to reduce chronic post-operative pain after breast surgery; the current status of th…
-
FDA approval · 2014-06-16FDA Approved: FENTANYL TRANSDERMAL — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for fentanyl transdermal submitted by SpecGx LLC, resulting in a regulatory update for the product.
-
FDA approval · 2014-04-16FDA Approved: MS CONTIN — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for MS CONTIN (morphine sulfate) filed by Rhodes Pharmaceuticals L.P., signaling an update relat…
-
FDA approval · 2014-02-04FDA Approved: OXYCONTIN — Supplemental Application (Purdue Pharma LP)
FDA approved a supplemental application for OXYCONTIN (oxycodone hydrochloride) submitted by Purdue Pharma LP.
-
CLINICAL_TRIALS trial_result · 2014-01-15Clinical Trial Update: A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain [Phase 3]
Phase 3 trial updates on safety and efficacy of JNS024 ER for chronic malignant tumor-related cancer pain in Japanese and Korean patients, w…
-
CLINICAL_TRIALS trial_result · 2013-10-11Clinical Trial Update: Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain [Phase 4]
A Phase 4 safety and efficacy study of OROS hydromorphone for cancer-related pain was terminated, with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain [Phase 4]
A Phase 4 clinical trial evaluating the efficacy and safety of the hydromorphone oral osmotic system (OROS) for cancer pain in Korean partic…
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain [Phase 3]
A Phase 3 trial comparing Osmotic Release Oral System hydromorphone hydrochloride with sustained-release morphine for cancer pain was termin…
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment [Phase 3]
A Phase 3 trial evaluating low-dose ketamine in combination with opioids for refractory cancer pain has completed.
-
CLINICAL_TRIALS trial_result · 2013-05-21Clinical Trial Update: A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain [Phase 2, Phase 3]
This update reports the results of a Phase 2/3 dose-finding study of the fentanyl JNS020 QD 1-day transdermal patch in cancer-related pain, …
-
FDA approval · 2013-04-19FDA Approved: FENTANYL — Supplemental Application (Aveva Drug Delivery Systems Inc.)
FDA approved a supplemental application for fentanyl submitted by Aveva Drug Delivery Systems, indicating approval of a revised fentanyl del…
-
FDA approval · 2013-04-15FDA Approved: MS CONTIN — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for MS CONTIN (morphine sulfate) from Rhodes Pharmaceuticals L.P.
-
CLINICAL_TRIALS trial_result · 2013-03-21Clinical Trial Update: A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain [Phase 2]
A Phase 2 clinical trial evaluating SSR411298 as an adjunctive treatment for persistent cancer pain has been terminated.
-
FDA approval · 2013-02-14FDA Approved: FENTANYL — Supplemental Application (Aveva Drug Delivery Systems Inc.)
FDA approved a supplemental application for fentanyl submitted by Aveva Drug Delivery Systems Inc., updating the marketing authorization for…
-
CLINICAL_TRIALS trial_result · 2013-02-11Clinical Trial Update: Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)
A completed case-control study investigated whether uncontrolled cancer pain predicts the development of depression in oncologic patients, w…
-
FDA approval · 2013-01-16FDA Approved: MORPHINE SULFATE — Original Application (Actavis Pharma, Inc.)
FDA approved Morphine Sulfate as an original generic ANDA for Actavis Pharma, enabling a generic formulation for pain management.
-
FDA approval · 2012-09-28FDA Approved: MORPHINE SULFATE EXTENDED RELEASE — Supplemental Application (Rhodes Pharmaceuticals L. P.)
The FDA approved a supplemental application for Morphine Sulfate Extended Release from Rhodes Pharmaceuticals L.P., updating labeling to sup…
-
CLINICAL_TRIALS trial_result · 2012-09-10Clinical Trial Update: Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol
Completed clinical trial from Vanderbilt-Ingram Cancer Center evaluating opioid titration in hospice cancer pain to identify barriers and to…
-
FDA approval · 2012-07-09FDA Approved: OXYCONTIN — Supplemental Application (Purdue Pharma LP)
The FDA approved a supplemental application for OxyContin (oxycodone hydrochloride) submitted by Purdue Pharma LP.
-
CLINICAL_TRIALS trial_result · 2012-05-07Clinical Trial Update: Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN) [Phase 3]
Phase 3 trial comparing FITpatch with standard opioid therapy for cancer-related chronic pain has completed, evaluating efficacy and safety.